The role of thromboxane A2 in complement activation-related pseudoallergy

Tamás Gyula Fülöp*, Josbert M. Metselaar, Gert Storm, János Szebeni

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Complement activation-related pseudoallergy (CARPA) is a hypersensitivity reaction occurring upon intravenous administration of numerous liposomal therapeutics, other nonbiological complex drugs and biologicals. It has a complex molecular and cellular mechanism that involves the production, actions and interactions of numerous vasoactive mediators in blood, including thromboxane A2 (TXA2). This short review focuses on the latter eicosanoid: Its role in CARPA, effects underlying some of the symptoms and experimental evidence for its rate-limiting role in pulmonary hypertension in pigs. Animal experiments and recent clinical observations suggest that the cyclooxygenase blocker indomethacin may represent an effective new approach to prevent liposome-induced CARPA, lending clinical relevance to better understand the involvement of TXA2 and other eicosanoids in this adverse immune effect.

Original languageEnglish
Pages (from-to)59-67
Number of pages9
JournalEuropean journal of nanomedicine
Volume9
Issue number2
DOIs
Publication statusPublished - 1 Apr 2017

Keywords

  • adverse drug reactions
  • allergy
  • anaphylatoxins
  • anaphylaxis
  • animal models
  • hemodynamic changes
  • hypersensitivity reactions
  • immune toxicity
  • pseudoallergy

Fingerprint Dive into the research topics of 'The role of thromboxane A<sub>2</sub> in complement activation-related pseudoallergy'. Together they form a unique fingerprint.

  • Cite this